Physician profile

Rita Claro

Dentist · Miami, FL

NPI 1164502357

$2,788.38

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$212.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Align Technology, INC. $2,091.24 2019-2023 Invisalign System - Moderate, Itero Element 5d Plus, Itero Element 5d Plus Lite
Neoss, INC. $382.99 2022-2023 Neoss Implant System
Ultradent Products INC $152.73 2022
Kerr Corporation $50.75 2021
Zimmer Biomet Holdings, INC. $42.51 2019
Keystone Dental INC. $28.57 2019
Orapharma, A Division of Bausch Health US, LLC $25.39 2021
Colgate Oral Pharmaceuticals, INC. $14.20 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rita Claro

$2,788.38

in general payments reported 2019-2025

Years
2019-2023
Top company
Align Technology, INC.

https://glasscript.com/doctor/97709/rita-claro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.